Generics BulletinSun Pharmaceutical Industries and its US Taro subsidiary have announced a further settlement to resolve historical price-fixing allegations in the US. The settlement agreement – which is still subject
Generics BulletinSun Pharma is once again under fire following a damning US Food and Drug Administration inspection of its sterile manufacturing facility in Halol, Gujarat. The 19-page Form 483 report, issued after a
ScripSun Pharma’s Leqselvi (deuruxolitinib) has finally hit the US market, pitting the JAK1/JAK2 inhibitor against its big pharma rivals, after the Indian group settled a patent dispute with Incyte. Leqsel
ScripFrontline Indian firms appear keen to accelerate product in-licensing deals with foreign companies and these efforts have now evolved from a “supplementary tactic” to a cornerstone of their strategy,